(Press-News.org) A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages. The data, published online March 27 in the journal Radiology, demonstrate that lung cancers found through annual CT screening are similar to those found in routine practice, both in terms of tumor growth rates and cell-type distribution. In fact, the report showed that 79 percent of the cases diagnosed through annual repeat CT scans were detected at clinical Stage I, the earliest and most treatable stage, compared to only 15 percent detected through traditional methods.
The study, which is the latest report from the International Early Lung Cancer Action Program (I-ELCAP), counters concerns that lung cancers diagnosed through annual repeat rounds of computed tomography (CT) screening may be of less serious varieties than those diagnosed in traditional clinical settings when symptoms are already present.
"We've previously shown that, similar to common screening methods such as mammography for breast cancer, annual CT scans are effective in early detection of lung cancer. However, there were concerns that the cancer found in these screenings were less serious than those found in routine practice in the clinical setting, and often resulted in excessive treatment," said Claudia I. Henschke, PhD, MD, Professor of Radiology at Mount Sinai School of Medicine and I-ELCAP principal investigator. "However, the data show that lung cancers detected with annual repeat rounds of CT scans are just as lethal and require equally aggressive treatment."
I-ELCAP is an international collaborative group of more than 60 participating institutes consisting of experts on lung cancer related diseases. Previous research from the group found that lung cancers detected through CT screening have an 80 percent cure rate compared to a 10 percent cure rate for lung cancers detected in the clinical setting.
"Lung cancer is by far the leading cause of cancer death among both men and women. However, when lung cancer is caught in an early, treatable stage, the cure rates are significantly higher," said Dr. Henschke. "It is recommended that people at high risk for lung cancer speak with their health care provider to discuss the benefits and risks of screening in order to make an informed decision about enrolling in a screening program."
Lung cancer accounts for more annual deaths than colon, breast, and prostate cancers combined. The American Cancer Society estimates that in 2012, approximately 226,160 new cases of lung cancer will be diagnosed in the United States and 160,340 Americans will die from the disease.
For this study, the researchers reviewed pooled results from the I-ELCAP database for 1993 to 2009, consisting of men and women at risk for lung cancer who underwent annual repeat rounds of CT screening. Researchers found 111 cases of lung cancer, 90 of which were non-small-cell cancers. Out of the 111 cases, 79 percent were clinical Stage I, the earliest and most treatable stage. Non-small-cell lung cancer is the most common form of lung cancer.
The researchers then compared their findings to a 2008 study published in the Journal of Thoracic Oncology analyzing the growth rates of non-small-cell lung cancers detected through traditional methods. The 2008 study found that only about 15 percent of those cancers were discovered in Stage I.
The researchers also found that while the first round of CT screening detected a higher proportion of slower-growing cancers than those detected in clinical practice, the subsequent annual repeat rounds of screening reflected what is found in clinical practice.
The investigators then analyzed volume doubling time – or growth rate – and cell-type distribution of the cancers. The mean volume doubling time for all cases was 136 days. Volume doubling times for lung cancers diagnosed in clinical practice ranged from 20 to 360 days. For the 90 non-small-cell cancers, mean volume doubling time was 154 days compared to 135 days in the 2008 study.
When researchers evaluated the cell-types of the cancers, they found the frequencies of small-cell carcinoma, which usually develops in the central areas of the lung, and adenocarcinoma, usually located on the outer surface of the lungs, to be approximately 19 percent and 50 percent, respectively. In the 2008 study these frequencies were nearly identical, at 20 percent and 50 percent.
In addition, the researchers found that 89 percent of the cancers that manifested as solid nodules had significantly faster volume doubling times than the sub-solid nodule cancers and may need a less aggressive diagnosis and treatment approach. The researchers defined cancerous nodules as solid if they obscured all of the lung tissue and sub-solid if they did not.
"Identifying the varying growth rates for specific lesion types should allow us to create a more tailored treatment for the patient," said Dr. Henschke.
###
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by US News and World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2011, US News and World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and US News and World Report and whose hospital is on the US News and World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.
For more information, visit http://www.mountsinai.org/.
Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter: @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy
END
PHILADELPHIA –- A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection. Understanding biological pathways involved in maintaining healthy nerves and clearing away damaged ones may offer scientists targets for drugs to mitigate neurodegenerative diseases such as Huntington's and Parkinson's, as well as aid in situations of acute nerve damage, such as spinal cord injury.
University of Pennsylvanian biologists developed the model in the adult fruit fly, Drosophila melanogaster.
"We ...
Women take longer to give birth today than did women 50 years ago, according to an analysis of nearly 140,000 deliveries conducted by researchers at the National Institutes of Health. The researchers could not identify all of the factors that accounted for the increase, but concluded that the change is likely due to changes in delivery room practice.
The study authors called for further research to determine whether modern delivery practices are contributing to the increase in labor duration.
The researchers compared data on deliveries in the early 1960s to data gathered ...
As any comic book lover knows, when superheroes band together the bad guys fall harder. The strength that comes in numbers is greater than the sum of its parts.
The same holds true, researchers have recently learned, when different species of crabs (genus Trapezia) and snapping shrimp (Alepheus lottini) in the central Pacific band together to defend their coral homes from hungry seastars. In these frequent conflicts "one-plus-one doesn't always equal two, sometime it is more," explains Seabird McKeon, a marine biologist at the National Museum of Natural History's Smithsonian ...
A small study from Massachusetts General Hospital (MGH) researchers found that online virtual communities may be an effective way to train patients in meditation and other mind/body techniques. The ability to learn and practice approaches that elicit the relaxation response – a state of deep rest that has been shown to alleviate stress-related symptoms – in a virtual environment could help surmount several barriers that can restrict participation.
"Our finding that a medical intervention – in this case teaching a mind/body approach that includes the relaxation response ...
The first typhoon of the northern hemisphere 2012 typhoon season is headed for landfall in Vietnam. NASA's Aqua and TRMM satellites have been providing forecasters with valuable data on Typhoon Pakhar, that includes rainfall rates, cloud extent and temperature.
The Tropical Rainfall Measuring Mission (TRMM) satellite flew almost directly over Pakhar when it was a newly formed tropical storm in the South China Sea on March 29, 2012 at 1122 UTC/4:22 p.m. Asia local time (or 7:22 a.m. EDT). The intensifying storm had wind speeds of about 45 knots (~52 mph/~83 kph) and was ...
Stir lots of small particles into water, and the resulting thick mixture appears highly viscous. When this dense suspension slips through a nozzle and forms a droplet, however, its behavior momentarily reveals a decidedly non-viscous side. University of Chicago physicists recorded this surprising behavior in laboratory experiments using high-speed photography that can capture action taking place in one hundred-thousandths of a second or less.
UChicago graduate student Marc Miskin and Heinrich Jaeger, the William J. Friedman and Alicia Townsend Friedman Professor in Physics, ...
CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration-resistant prostate cancer (CRPC)," abstract ...
CHICAGO — Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand ...
CHICAGO — The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.
Anthony M. Joshua, M.B.B.S., Ph.D., staff medical oncologist at the Princess Margaret Hospital, University Health Network in Toronto, Ontario, Canada, presented the data at the AACR Annual Meeting 2012, held here March 31 - April 4.
Metformin is the most commonly prescribed medication for diabetes. Prior laboratory research has suggested that metformin may ...
CHICAGO — The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.
"Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea Necchi, M.D., faculty member in the department of medicine at Fondazione ...
